Medpace Holdings, Inc. — Q3 2021 Form 10-Q
Business context and reporting period. The filing covers the quarter and nine months ended September 30, 2021. Medpace is a global clinical research organization providing Phase I–IV drug and medical-device development services. It reported approximately 4,400 employees across 40 countries.
Financial performance
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $295.6m | $230.4m | $833.8m | $666.2m |
| Operating income | $53.7m | $46.4m | $143.8m | $112.1m |
| Net income | $48.6m | $41.5m | $131.8m | $94.5m |
| Diluted EPS | $1.29 | $1.09 | $3.49 | $2.50 |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $192.4m | $153.2m |
- Q3 revenue rose 28.3%; operating income rose 15.7% and net income rose 17.2%. Approximate operating margin declined to 18.2% from 20.1%, and net margin to 16.4% from 18.0%.
- For the first nine months, revenue grew 25.2%, operating income 28.3%, and net income 39.5%. Approximate operating margin increased to 17.2% from 16.8%; net margin increased to 15.8% from 14.2%.
- Direct costs increased 33.5% in Q3 and 26.2% year to date, driven by reimbursed expenses and higher personnel costs, including severance. Q3 reimbursed out-of-pocket expenses increased $27.3m and personnel costs, including severance, increased $20.1m year over year.
- Effective tax rate was 11.3% for Q3 and 9.7% for nine months, versus 11.8% and 17.0%, respectively, in 2020; lower rates primarily reflected excess tax benefits from share-based compensation.
- Cash and cash equivalents were $398.4m at September 30, 2021, up from $277.8m at December 31, 2020. Total assets were $1.58b and shareholders’ equity $898.1m.
- Nine-month operating cash flow was $192.4m; investing cash outflow was $22.2m, primarily capital expenditures of $19.2m; financing cash outflow was $46.9m, chiefly $62.1m of share repurchases, partly offset by stock-option proceeds.
- No borrowings were outstanding under the $50m unsecured credit facility; $49.8m remained available and $0.2m of letters of credit were outstanding. The facility expires March 31, 2022. Lease liabilities totaled $143.2m.
Changes, outlook, risks and unusual items
- Net new business awards were $408.0m in Q3 and $1.152b for nine months. Backlog reached $1.850b, up 29.0% from September 2020; management expected $1.005–$1.025b to convert to revenue over the next 12 months. Backlog is not a guaranteed revenue forecast and can change with cancellations, scope, timing and foreign exchange.
- The company reported approximately $1.9b of remaining performance obligations for active projects. This measure and backlog are separately described in the filing.
- No specific financial guidance was provided. Management described continued organic growth and possible selective bolt-on acquisitions, funded from cash, operating cash flow and, if needed, credit facilities.
- Management said COVID-19 continued to disrupt clinical-site access, patient recruitment and trial start-ups, and could lead to cancellations or customer funding constraints. It characterized expected effects as temporary but said future financial impact could not be reasonably estimated.
- Revenue growth was concentrated in areas including Oncology, Metabolic and Central Nervous System. Foreign-currency movements affected results and backlog; most contracts and transactions are U.S.-dollar denominated, with the Euro the largest foreign-currency exposure.
- The company repurchased $62.1m of shares in the first nine months, with $190.5m of authorization remaining at quarter end. The CEO and other company personnel have disclosed relationships with certain customers and property or travel-service providers; related-party revenue was $8.7m in Q3 and $23.9m year to date.
- In Q3, Medpace extended the term of its related-party headquarters lease through November 2032 after determining renewal was reasonably certain. Legal proceedings and purchase commitments were described as immaterial; project-supply purchase commitments totaled $12.2m.
Most important facts for investors to verify
- Whether backlog and new awards convert to revenue at the expected pace, given cancellation rights and COVID-related recruitment, site-access and funding risks.
- Whether rising personnel and reimbursed project costs can be managed while sustaining operating margins.
- The composition and ongoing significance of related-party revenue, leases and service expenses, including governance and terms.
- Cash generation, share repurchase pace, capital spending and credit-facility renewal before its March 2022 expiration.
- Foreign-exchange exposure and the durability of the unusually low effective tax rate, which benefited from share-based compensation tax benefits.